
Kestra Medical Technologies, Ltd.: updates and filings
Price
$26.63
November 19, 2026Market cap $1.6B
What Ploutos Investor adds for Kestra Medical Technologies
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from FY2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Sep 14, 2026next Dec 14, 2026
An estimate from when it has reported before, which has been regular. The company announces the date itself.
September 2026
July 2026
March 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Sep 14, 2026Quarterly reportfor the period to Jul 31, 2026Form10-Q
- Sep 14, 2026Results of operationsForm8-K
- Sep 10, 2026Shareholder voteForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 28, 2026Annual report to shareholdersfor the period to Apr 30, 2026FormARS
- Jul 28, 2026Additional annual meeting materialFormDEFA14A
- Jul 28, 2026Annual meeting proxy statementFormDEF 14A
- Jul 14, 2026Annual reportfor the period to Apr 30, 2026Form10-K
- Jul 14, 2026Material agreement entered, material agreement ended, results of operations, new material financial obligationForm8-K
- Apr 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 1, 2026Shelf registration for future offeringsFormS-3ASR
- Mar 18, 2026Shares registered for employeesFormS-8
- Mar 17, 2026Quarterly reportfor the period to Jan 31, 2026Form10-Q
- Mar 17, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Dec 11, 2025Quarterly reportfor the period to Oct 31, 2025Form10-Q
- Dec 11, 2025Results of operationsForm8-K
- Dec 4, 2025Material agreement enteredForm8-K
- Dec 2, 2025FilingFormEFFECT
- Dec 2, 2025FilingFormS-1MEF
- Dec 1, 2025Correspondence with the SECFormCORRESP
- Dec 1, 2025Correspondence with the SECFormCORRESP
- Dec 1, 2025FilingFormS-1
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Sep 14, 2026 | 10-Q | Quarterly reportfor the period to Jul 31, 2026 | Document |
| Sep 14, 2026 | 8-K | Results of operations | Document |
| Sep 10, 2026 | 8-K | Shareholder vote | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 28, 2026 | ARS | Annual report to shareholdersfor the period to Apr 30, 2026 | Document |
| Jul 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jul 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jul 14, 2026 | 10-K | Annual reportfor the period to Apr 30, 2026 | Document |
| Jul 14, 2026 | 8-K | Material agreement entered, material agreement ended, results of operations, new material financial obligation | Document |
| Apr 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 1, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Mar 18, 2026 | S-8 | Shares registered for employees | Document |
| Mar 17, 2026 | 10-Q | Quarterly reportfor the period to Jan 31, 2026 | Document |
| Mar 17, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Dec 11, 2025 | 10-Q | Quarterly reportfor the period to Oct 31, 2025 | Document |
| Dec 11, 2025 | 8-K | Results of operations | Document |
| Dec 4, 2025 | 8-K | Material agreement entered | Document |
| Dec 2, 2025 | EFFECT | Filing | Document |
| Dec 2, 2025 | S-1MEF | Filing | Document |
| Dec 1, 2025 | CORRESP | Correspondence with the SEC | Document |
| Dec 1, 2025 | CORRESP | Correspondence with the SEC | Document |
| Dec 1, 2025 | S-1 | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 25, 2021.
The full analysis
What do Kestra Medical Technologies's filings show?
The filings are where every one of Kestra Medical Technologies's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.